Formerly Somite AI, the rebranded company aims to broaden the regenerative medicine landscape by building AI models that ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

Expected rapid advances in CAR T and other cellular therapies may expand treatment options not only in cancer but also in ...

The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

Orca Bio has disclosed $250 million in funding, flooding its balance sheet with cash to buoy preparations for the ...

Colleen Mabasa, a patient with multiple myeloma, discusses her CAR T-cell therapy journey and the pivotal role self-advocacy ...

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...

In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...

Some parts of our bodies bounce back from injury in fairly short order. The outer protective layer of the eye—called the ...

The American Society of Gene & Cell Therapy (ASGCT), the leading professional organization for the advancement of cell and gene therapies (CGTs), and the Orphan Therapeutics Accelerator (OTXL), a ...

Glioblastoma remains one of the most challenging solid tumors to treat due to its highly immunosuppressive tumor microenvironment.